FORUS has secured an exclusive Canadian distribution agreement with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for the commercialization of XPOVIO^® (selinexor), an FDA-approved cancer medicine for adults with multiple myeloma; the second most common blood cancer and lymphoma. Every year, 3,400 Canadians are diagnosed with multiple myeloma, and sadly 1,600 die from the disease.

FORUS will build its pipeline with Canadian assets in discovery and development as well as other innovative products either in late stage-clinical development or with regulatory authorizations in jurisdictions outside of Canada.